6 results
2.1 Primary objectiveTo assess the rate of no progression (NPR) at 8 weeks following treatment with the combination of gefitinib and fulvestrant in EGFR mutated patients who failed previous treatment with reversible EGFR TKI*s (gefitinib or…
Primary* To determine the maximum tolerated dose or recommended phase 2 dose of oral BYL719 as single agent and in combination with fulvestrantSecondary* To assess the overall safety and tolerability of BYL719 as single agent and in combination with…
Optimise post PVI management using ambulant continuous patient-driven eHealth monitoring after catheter ablation in the treatment of atrial fibrillation.Primary Objective:1) Determine the effect of eHealth on clinical management, outcomes and…
The aim of this study is to quantify residual ER binding sites during fulvestrant therapy, compared to the tracer uptake prior to fulvestrant therapy.
To investigate prospectively how the "TAMRO-profile" performs in a pre-operative treatment setting. In addition we can examine whether the profile is specific for tamoxifen or is predictive for endocrine resistance in general. Also the…
The purpose of the research trial is to assess if heart failure markers and clinical end-points are influenced by 24 hours of AV-node stimulation (AVNS) in acutely decompensated heart failure (ADHF) patients.Primary Objective(s)The primary objective…